both interesting and instructive. I have the feeling that Dr Young is living a long way from the cutting edge of modern management budgeting. While our DHA Directorate is ankle deep in computers costing thousands of pounds, I have only just managed to scrounge a secondhand computer surplus to the requirements of our finance department. This, at least, will allow us to put some of our more routine waiting lists onto disc, but it has been largely a matter of luck. The clinical staff have not been encouraged to use computers in their work, and the computers themselves have always been taken from the medical equipment budget. Since it has always been a matter of balancing computers against hard equipment such as replacement monitors, there has been no possibility of supplying ourselves with these aids for diagnosis Having reduced their patients' prognoses by choosing to use single drugs, the King's Group refuse to use what they admit is the most effective single agent, i.e. adriamycin which, they say, is 'extremely toxic'. This statement is scientifically meaningless. The side effects of any drug are not only a function of the chemical properties of the compound as such but also of the way in which it is given. It is illogical to make sweeping generalizations about the side effects of drugs without stating how they were given and what steps were taken to minimize such effects. For example, the side effects of most combination cancer chemotherapy programmes, including those with adriamycin, can be significantly reduced by admitting the patients to hospital, giving them high doses of combined antiemetics as a premedication and administering the drugs in full doses over 24 h instead of over several days. Approximately 80% of patients treated in this way will have no vomiting or diarrhoea, only rarely experience nausea, and lead a virtually normal life between treatment cycles. Apart from temporary alopecia there is not a single side effect of adriamycin which cannot be avoided by giving the drug by this method and observing a few simple and well known precautions. The validity of this approach has been extensively tested over the last 15 years 4 -6 and confirmed by several different groups7,8
This raises the question of whether these patients are being informed that they are not being given the currently best available treatment. If they are not so informed, this poses a serious ethical dilemma: either the King's Group are unaware of facts which it is their duty to know or they are giving suboptimal treatment to uninformed patients. Either way, in my opinion, the study is unethical. Failure to realize that anticancer drugs can now be given much more safely and with far fewer side effects than in the past is wrong for two reasons: (1), many patients receiving chemotherapy are sutTering from side effects which could largely be prevented, and (2), the constant emphasis on only the negative aspects of the drug treatment of breast cancer means that many patients with advanced disease are being deprived of the benefits of optimum chemotherapy as are those with 'high risk' tumours at the time of diagnosis, many of whom are being given adjuvant tamoxifen alone instead of tamoxifen plus combination chemotherapy. This situation will never improve unless we base our
